-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Recently, the letter of intent for listing on the Science and Technology Innovation Board released by Rongchang Bio showed that the company issued 54.
4263 million shares for the first time and planned to raise 4 billion yuan for new biological drug industrialization projects, anti-tumor antibody new drug research and development projects, autoimmunity and ophthalmic diseases.
Antibody new drug research and development projects and supplementary working capital projects
.
According to the data, the company is an innovative drug company focusing on the field of therapeutic antibody drugs such as antibody drug conjugates (ADC), antibody fusion proteins, monoclonal antibodies and double antibodies
.
From the perspective of product pipeline, Rongchang Bio has developed more than 20 candidate innovative drug projects, of which Taitacept (RC18), Vidicitumumab (RC48) and RC28 are the company's three core products, and RC48 is the company's three core products.
A Chinese ADC innovative drug product that has been granted breakthrough therapy designation by the US FDA
.
At present, RC18 and RC48 have been commercialized and will enter the new version of the National Medical Insurance Drug List by the end of 2021
.
RC-28 has entered the phase II clinical stage
.
In addition, Rongchang Bio has 4 new class 1 drugs that have entered the clinical trial stage (excluding new drugs that have been marketed to develop new indications), namely RC88, RC98, RC108 and RC118, all of which are in the clinical phase I stage
.
Among them, RC88, RC108, and RC118 are ADC drugs, and the corresponding targets of RC88 (MSLN) and RC118 (CLDN18) are not currently available in the world
.
In addition, Rongchang Bio has 10 drug candidates that are still in the IND preparation stage
.
It is understood that the two hot new drug development areas of ADC drugs and bispecific antibodies are the current focus of Rongchang Bio.
Among them, there are 7 ADC drugs and 5 bispecific antibody drugs
.
ADC is a new class of targeted drugs composed of monoclonal antibodies, cytotoxic drugs and linkers that connect the two.
It uses the targeting of antibodies to selectively deliver cytotoxic molecules to tumor cells.
Cancer while avoiding effects on healthy cells
.
At present, the global ADC drug market scale is as high as 10 billion US dollars, and there are more than 600 new ADC drug projects under research, but only 16 new ADC drugs have been approved for marketing, including trastuzumab emmet, vebotuzumab, and Goxa.
Tutuzumab, Tilimumab, Velbutuximab,
etc.
Looking at China, the number of tumor patients in China is huge, and the ADC drug market has broad prospects, which has also stimulated the enthusiasm of enterprises for research and development, and major pharmaceutical companies have joined the competition on the track
.
Among them, the ADC products of pharmaceutical companies such as Bio-Otai and TOT have entered the clinical phase III, and the products of Hengrui, Kelun Pharmaceutical and other companies are in the clinical phase II
.
It is worth mentioning that the Nuggets ADC track is not easy, and some companies have decided to withdraw from the competition considering the fierce market competition
.
For example, in 2021, Bio-Tech has announced to terminate the clinical trials and development of BAT8001 and BAT8003.
The reason is that considering the changes in the market pattern in the field of Trop2 ADC, and the similarities between BAT8003 and BAT8001 in some technical characteristics, there is a high clinical Development and market risks, it will be difficult for the drug to gain an advantage in the competition with many targeted anti-tumor drugs, so research and development and trials are terminated
.
CITIC Securities released a research report saying that with the rapid development of the ADC field at home and abroad, especially the intensified competition for the same type of targets, efficient clinical promotion and differentiated indication development strategies will become the market for ADC drug layout pharmaceutical companies in the future.
The center of gravity of competitive advantage
.
Disclaimer: Under no circumstances does the information or opinions expressed in this article constitute investment advice to anyone
.
4263 million shares for the first time and planned to raise 4 billion yuan for new biological drug industrialization projects, anti-tumor antibody new drug research and development projects, autoimmunity and ophthalmic diseases.
Antibody new drug research and development projects and supplementary working capital projects
.
According to the data, the company is an innovative drug company focusing on the field of therapeutic antibody drugs such as antibody drug conjugates (ADC), antibody fusion proteins, monoclonal antibodies and double antibodies
.
From the perspective of product pipeline, Rongchang Bio has developed more than 20 candidate innovative drug projects, of which Taitacept (RC18), Vidicitumumab (RC48) and RC28 are the company's three core products, and RC48 is the company's three core products.
A Chinese ADC innovative drug product that has been granted breakthrough therapy designation by the US FDA
.
At present, RC18 and RC48 have been commercialized and will enter the new version of the National Medical Insurance Drug List by the end of 2021
.
RC-28 has entered the phase II clinical stage
.
In addition, Rongchang Bio has 4 new class 1 drugs that have entered the clinical trial stage (excluding new drugs that have been marketed to develop new indications), namely RC88, RC98, RC108 and RC118, all of which are in the clinical phase I stage
.
Among them, RC88, RC108, and RC118 are ADC drugs, and the corresponding targets of RC88 (MSLN) and RC118 (CLDN18) are not currently available in the world
.
In addition, Rongchang Bio has 10 drug candidates that are still in the IND preparation stage
.
It is understood that the two hot new drug development areas of ADC drugs and bispecific antibodies are the current focus of Rongchang Bio.
Among them, there are 7 ADC drugs and 5 bispecific antibody drugs
.
ADC is a new class of targeted drugs composed of monoclonal antibodies, cytotoxic drugs and linkers that connect the two.
It uses the targeting of antibodies to selectively deliver cytotoxic molecules to tumor cells.
Cancer while avoiding effects on healthy cells
.
At present, the global ADC drug market scale is as high as 10 billion US dollars, and there are more than 600 new ADC drug projects under research, but only 16 new ADC drugs have been approved for marketing, including trastuzumab emmet, vebotuzumab, and Goxa.
Tutuzumab, Tilimumab, Velbutuximab,
etc.
Looking at China, the number of tumor patients in China is huge, and the ADC drug market has broad prospects, which has also stimulated the enthusiasm of enterprises for research and development, and major pharmaceutical companies have joined the competition on the track
.
Among them, the ADC products of pharmaceutical companies such as Bio-Otai and TOT have entered the clinical phase III, and the products of Hengrui, Kelun Pharmaceutical and other companies are in the clinical phase II
.
It is worth mentioning that the Nuggets ADC track is not easy, and some companies have decided to withdraw from the competition considering the fierce market competition
.
For example, in 2021, Bio-Tech has announced to terminate the clinical trials and development of BAT8001 and BAT8003.
The reason is that considering the changes in the market pattern in the field of Trop2 ADC, and the similarities between BAT8003 and BAT8001 in some technical characteristics, there is a high clinical Development and market risks, it will be difficult for the drug to gain an advantage in the competition with many targeted anti-tumor drugs, so research and development and trials are terminated
.
CITIC Securities released a research report saying that with the rapid development of the ADC field at home and abroad, especially the intensified competition for the same type of targets, efficient clinical promotion and differentiated indication development strategies will become the market for ADC drug layout pharmaceutical companies in the future.
The center of gravity of competitive advantage
.
Disclaimer: Under no circumstances does the information or opinions expressed in this article constitute investment advice to anyone
.
